DC4U Technologies is a biotechnology startup established in 2006 with a focus on immunological application of glycobiology. The company's GlycoDC™ Platform has the capability to modulate the immune system, making it applicable to antigen-based therapeutics and products. Headquartered in The Netherlands, DC4U Technologies secured a grant investment on 25 October 2022 from Eureka Network. With its innovative platform technology and expertise in immunology, this startup presents a promising investment opportunity in the biotechnology sector.
No recent news or press coverage available for DC4U Technologies.